micro-community-banner
  • Saved
Perspectives on weight control in diabetes - Tirzepatide - PubMed

Perspectives on weight control in diabetes - Tirzepatide - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37279858/

The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....

Conclusions/Relevance: These findings suggest that the robust weight loss and associated changes are important contributors to the clinical profile of tirzepatide for the treatment of T2D diabetes and serve as the basis for further investigations including clinical outcomes.

  • Saved

Conclusions: The combination of aerobic training and semaglutide treatment synergistically improved β-cell secretory function.

  • Saved

Relevance: Novo Nordisk, the drug’s developer, announced the study’s topline results in a press release. On average, participants experienced a 15.1% decrease in weight after receiving the medication, regardless of treatment adherence, compared with a 2.4% weight loss with the placebo. The amount of weight loss with oral semaglutide was...

  • Saved
Clinical outcomes associated with drugs for obesity and overweight: A systematic review and network meta-analysis of randomized controlled trials - PubMed

Clinical outcomes associated with drugs for obesity and overweight: A systematic review and network meta-analysis of randomized controlled trials - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37254688/

Among adults with obesity or overweight, semaglutide and phentermine/topiramate were associated with greater body weight loss and waist circumference reduction at 12 months than all other drugs, and lower or...

Conclusions: Among adults with obesity or overweight, semaglutide and phentermine/topiramate were associated with greater body weight loss and waist circumference reduction at 12 months than all other drugs, and lower or no significant difference in risks of withdrawal. There was no evidence that drugs approved for weight management had...

  • Saved
Greater Combined Reductions of HbA1c ≥ 1.0% and Body Weight Loss ≥ 5.0% or ≥ 10.0% with Orally Administered Semaglutide Versus Comparators - PubMed

Greater Combined Reductions of HbA1c ≥ 1.0% and Body Weight Loss ≥ 5.0% or ≥ 10.0% with Orally Administered Semaglutide Versus Comparators - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37256503/

The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....

Conclusion: In PIONEER 1-5 and 8, odds of achieving clinically relevant reductions in both HbA1c and body weight were significantly greater with orally administered semaglutide versus comparators.